The Africa In-Vitro Diagnostics Market Trends 2030 Forecast

Name: The Africa In-Vitro Diagnostics Market Trends 2030 Forecast
Creator: Next Move Strategy Consulting
Published: 2025-05-02T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

Africa In-Vitro Diagnostic Market By Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), By Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Others), By Testing Site/Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and Others), By Application (Infectious Diseases, Oncology, Cardiovascular Health, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Market Overview

The Africa In-Vitro Diagnostics Market size was valued at USD 0.93 billion in 2023, and is predicted to reach USD 1.45 billion by 2030, at a CAGR of 6% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.

IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology. These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Increasing Healthcare Investments Drives the Market Growth in Africa

In Ghana, the in-vitro diagnostics market is showing a steady growth due to investments allocated by various organizations to improve healthcare services. In 2022, the World Bank sanctioned USD 150 million in support for the Primary Health Care Investment Program. With a particular emphasis on healthcare investment, the funding intends to strengthen the quality and accessibility of primary health care services in Ghana.

This strategic investment is poised to drive the Africa in-vitro diagnostics market growth by fostering a conducive environment for healthcare innovation and infrastructure development.

By strengthening primary health care systems, including diagnostic facilities, the initiative enhances the capacity to diagnose and manage diseases effectively, thereby boosting the demand for in-vitro diagnostics in the region.

The Rising Prevalence of Heart Diseases Boosts the Market Growth

The alarming rate of heart diseases in South Africa drives the demand for advanced diagnostics solutions such as in-vitro diagnostics. As reported by the Heart & Stroke Foundation, the country witnesses 215 deaths from heart disease or strokes each day.

Moreover, every hour, 5 individuals experience heart attacks, while 10 suffer from strokes. This concerning scenario underscores the urgent need for early detection and diagnosis of cardiovascular diseases. IVD enables early detection by identifying cardiac biomarkers associated with heart disease, allowing for intervention before symptoms manifest.

Additionally, immunodiagnostic tests assess individual cardiovascular risk factors, guiding tailored preventive strategies and for diagnosed patients. In-vitro diagnostics facilitates disease monitoring, ensuring timely adjustments to treatment plans for optimal outcomes.

High Research, Development, and Regulatory Approval Costs Hinder the Market Expansion

High costs associated with research, development, and regulatory approval are significant factors restraining the Africa IVD market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.

Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing (POCT) Solutions in IVD Creates Market Opportunity

Point-of-care testing (POCT) is poised to significantly drive the Africa IVD market demand, in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the Africa in-vitro diagnostics industry include F. Hoffmann-La Roche Ltd (Roche Diagnostics), Abbott Laboratories (Abbott Diagnostics), Siemens Healthineers AG, Beckman Coulter, Inc. (Beckman Coulter Diagnostics), Becton Dickinson and Company (BD), bioMérieux SA, Sysmex Corporation, QuidelOrtho Corporation, DiaSorin S.p.A., QIAGEN N.V., Hologic, Inc., Werfen, S.A., Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray), Bio-Rad Laboratories, Inc., Randox, and others.

Africa In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

By Region

Africa
- South Africa
- Nigeria
- Kenya
- Egypt
- Morocco
- Ghana
- Other Countries

Key Players

F. Hoffmann-La Roche Ltd (Roche Diagnostics)
Abbott Laboratories (Abbott Diagnostics)
Siemens Healthineers AG
Beckman Coulter, Inc. (Beckman Coulter Diagnostics)
Becton Dickinson and Company (BD)
bioMérieux SA
Sysmex Corporation
QuidelOrtho Corporation
DiaSorin S.p.A.
QIAGEN N.V.
Hologic, Inc.
Werfen, S.A.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray)
Bio-Rad Laboratories, Inc.
Randox

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 0.93 billion
Revenue Forecast in 2030	USD 1.45 billion
Value Growth Rate	CAGR of 6.0% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increasing Healthcare Investments Drive the Market Growth. Rising Prevalence of Heart Diseases Boosts the Market Growth.
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Jayanta Das is a senior research analyst delivering high-impact market intelligence across global markets. He leads comprehensive studies covering market assessment, forecasting, competitive evaluation, regulatory review, and trend analysis. Known for his structured and methodical approach, Jayanta excels at converting complex datasets into clear, decision-ready insights for leadership teams. His work supports strategic planning through credible sourcing, analytical precision, strong validation frameworks, and well-structured, business-focused reporting that enables confident decision-making.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 INCREASING HEALTHCARE INVESTMENTS DRIVES THE MARKET GROWTH IN AFRICA
  2. 5.1.2 THE RISING PREVALENCE OF HEART DISEASES BOOSTS THE MARKET GROWTH
3. 5.2 CHALLENGES
4. 1. 5.2.1 HIGH RESEARCH, DEVELOPMENT, AND REGULATORY APPROVAL COSTS HINDER THE MARKET EXPANSION
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 INTRODUCTION OF POINT-OF-CARE TESTING (POCT) SOLUTIONS IN IVD CREATES MARKET OPPORTUNITY

1. 6.1 OVERVIEW
2. 6.2 REAGENTS
3. 1. 6.2.1 REAGENTS MARKET, BY COUNTRY
4. 6.3 INSTRUMENTS
5. 1. 6.3.1 INSTRUMENTS MARKET, BY COUNTRY
6. 6.4 SOFTWARE AND SERVICES
7. 1. 6.4.1 SOFTWARE AND SERVICES MARKET, BY COUNTRY

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS
3. 1. 7.2.1 IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.2.1.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY
    2. 7.2.1.2 RAPID TESTS MARKET, BY COUNTRY
    3. 7.2.1.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY
    4. 7.2.1.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY COUNTRY
    5. 7.2.1.5 RADIOIMMUNOASSAY (RIA) MARKET, BY COUNTRY
    6. 7.2.1.6 WESTERN BLOT MARKET, BY COUNTRY
  3. 7.2.2 IMMUNODIAGNOSTICS MARKET, BY COUNTRY
4. 7.3 HEMATOLOGY
5. 1. 7.3.1 HEMATOLOGY MARKET, BY COUNTRY
6. 7.4 MOLECULAR DIAGNOSTICS
7. 1. 7.4.1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
  2. 1. 7.4.1.1 PCR MARKET, BY COUNTRY
    2. 1. 7.4.1.1.1 MONOPLEX PCR
      2. 7.4.1.1.2 MULTIPLEX PCR
    3. 7.4.1.2 INAAT MARKET, BY COUNTRY
    4. 7.4.1.3 HYBRIDIZATION MARKET, BY COUNTRY
    5. 7.4.1.4 DNA DIAGNOSTICS MARKET, BY COUNTRY
    6. 7.4.1.5 MICROARRAY MARKET, BY COUNTRY
    7. 7.4.1.6 OTHER MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
  3. 7.4.2 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
8. 7.5 TISSUE DISGNOSTICS
9. 1. 7.5.1 TISSUE DISGNOSTICS MARKET, BY COUNTRY
10. 7.6 CLINICAL CHEMISTRY
11. 1. 7.6.1 CLINICAL CHEMISTRY MARKET, BY TECHNIQUE
  2. 1. 7.6.1.1 BASIC METABOLIC PANEL MARKET, BY COUNTRY
    2. 7.6.1.2 LIVER PANEL MARKET, BY COUNTRY
    3. 7.6.1.3 RENAL PROFILE MARKET, BY COUNTRY
    4. 7.6.1.4 LIPID PROFILE MARKET, BY COUNTRY
    5. 7.6.1.5 THYROID FUNCTION PANEL MARKET, BY COUNTRY
    6. 7.6.1.6 ELECTROLYTE PANEL MARKET, BY COUNTRY
    7. 7.6.1.7 SPECIALITY CHEMICALS MARKET, BY COUNTRY
  3. 7.6.2 CLINICAL CHEMISTRY MARKET, BY COUNTRY
12. 7.7 OTHER IVD TECHNIQUES
13. 1. 7.7.1 OTHER IVD TECHNIQUES MARKET, BY COUNTRY

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES
3. 1. 8.2.1 INFECTIOUS DISEASES MARKET, BY COUNTRY
4. 8.3 CANCER
5. 1. 8.3.1 CANCER MARKET, BY COUNTRY
6. 8.4 CARDIAC DISEASES
7. 1. 8.4.1 CARDIAC DISEASES MARKET, BY COUNTRY
8. 8.5 IMMUNE SYSTEM DISORDERS
9. 1. 8.5.1 IMMUNE SYSTEM DISORDERS MARKET, BY COUNTRY
10. 8.6 NEPHROLOGICAL DISEASES
11. 1. 8.6.1 NEPHROLOGICAL DISEASES MARKET, BY COUNTRY
12. 8.7 GASTROINTESTINAL DISEASES
13. 1. 8.7.1 GASTROINTESTINAL DISEASES MARKET, BY COUNTRY
14. 8.8 OTHER INDICATIONS
15. 1. 8.8.1 OTHER INDICATIONS MARKET, BY COUNTRY

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY
3. 1. 9.2.1 STAND ALONE LABORATORY MARKET, BY COUNTRY
4. 9.3 HOSPITALS
5. 1. 9.3.1 HOSPITALS MARKET, BY COUNTRY
6. 9.4 ACADEMICS AND MEDICAL SCHOOLS
7. 1. 9.4.1 ACADEMICS AND MEDICAL SCHOOLS MARKET, BY COUNTRY
8. 9.5 POINT OF CARE TESTING
9. 1. 9.5.1 POINT OF CARE TESTING MARKET, BY COUNTRY
10. 9.6 OTHER END-USERS
11. 1. 9.6.1 OTHER END-USERS MARKET, BY COUNTRY

1. 10.1 OVERVIEW
2. 10.2 SOUTH AFRICA
3. 1. 10.2.1 SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.2.2 SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.2.3 SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.2.4 SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET, BY END-USER
4. 10.3 NIGERIA
5. 1. 10.3.1 NIGERIA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.3.2 NIGERIA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.3.3 NIGERIA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.3.4 NIGERIA IN-VITRO DIAGNOSTICS MARKET, BY END-USER
6. 10.4 GHANA
7. 1. 10.4.1 GHANA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.4.2 GHANA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.4.3 GHANA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.4.4 GHANA IN-VITRO DIAGNOSTICS MARKET, BY END-USER
8. 10.5 KENYA
9. 1. 10.5.1 KENYA IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.5.2 KENYA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.5.3 KENYA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.5.4 KENYA IN-VITRO DIAGNOSTICS MARKET, BY END-USER
10. 10.6 MOROCCO
11. 1. 10.6.1 MOROCCO IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.6.2 MOROCCO IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.6.3 MOROCCO IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.6.4 MOROCCO IN-VITRO DIAGNOSTICS MARKET, BY END-USER
12. 10.7 EGYPT
13. 1. 10.7.1 EGYPT IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.7.2 EGYPT IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.7.3 EGYPT IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.7.4 EGYPT IN-VITRO DIAGNOSTICS MARKET, BY END-USER
14. 10.8 OTHER AFRICAN COUNTRIES
15. 1. 10.8.1 OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT TYPE
  2. 10.8.2 OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
  3. 10.8.3 OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
  4. 10.8.4 OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET, BY END-USER

1. 11.1 ABBOTT LABORATORIES
2. 1. 11.1.1 COMPANY OVERVIEW
  2. 11.1.2 COMPANY SNAPSHOT
  3. 11.1.3 OPERATING BUSINESS SEGMENTS
  4. 11.1.4 PRODUCT PORTFOLIO
  5. 11.1.5 BUSINESS PERFORMANCE
  6. 11.1.6 BUSINESS SEGMENTS
  7. 11.1.7 GEOGRAPHIC SEGMENTS
  8. 11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.1.9 PRIMARY MARKET COMPETITORS
3. 11.2 ROCHE HOLDING AG
4. 1. 11.2.1 COMPANY OVERVIEW
  2. 11.2.2 COMPANY SNAPSHOT
  3. 11.2.3 OPERATING BUSINESS SEGMENTS
  4. 11.2.4 PRODUCT PORTFOLIO
  5. 11.2.5 BUSINESS PERFORMANCE
  6. 11.2.6 BUSINESS SEGMENTS
  7. 11.2.7 GEOGRAPHIC SEGMENTS
  8. 11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.2.9 PRIMARY MARKET COMPETITORS
5. 11.3 MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.
6. 1. 11.3.1 COMPANY OVERVIEW
  2. 11.3.2 COMPANY SNAPSHOT
  3. 11.3.3 OPERATING BUSINESS SEGMENTS
  4. 11.3.4 PRODUCT PORTFOLIO
  5. 11.3.5 BUSINESS PERFORMANCE
  6. 11.3.6 BUSINESS SEGMENTS
  7. 11.3.7 GEOGRAPHIC SEGMENTS
  8. 11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.3.9 PRIMARY MARKET COMPETITORS
7. 11.4 THERMO FISHER SCIENTIFIC INC
8. 1. 11.4.1 COMPANY OVERVIEW
  2. 11.4.2 COMPANY SNAPSHOT
  3. 11.4.3 OPERATING BUSINESS SEGMENTS
  4. 11.4.4 PRODUCT PORTFOLIO
  5. 11.4.5 BUSINESS PERFORMANCE
  6. 11.4.6 BUSINESS SEGMENTS
  7. 11.4.7 GEOGRAPHIC SEGMENTS
  8. 11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.4.9 PRIMARY MARKET COMPETITORS
9. 11.5 DANAHER CORPORATION
10. 1. 11.5.1 COMPANY OVERVIEW
  2. 11.5.2 COMPANY SNAPSHOT
  3. 11.5.3 OPERATING BUSINESS SEGMENTS
  4. 11.5.4 PRODUCT PORTFOLIO
  5. 11.5.5 BUSINESS PERFORMANCE
  6. 11.5.6 BUSINESS SEGMENTS
  7. 11.5.7 GEOGRAPHIC SEGMENTS
  8. 11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.5.9 PRIMARY MARKET COMPETITORS
11. 11.6 BECTON, DICKINSON AND COMPANY
12. 1. 11.6.1 COMPANY OVERVIEW
  2. 11.6.2 COMPANY SNAPSHOT
  3. 11.6.3 OPERATING BUSINESS SEGMENTS
  4. 11.6.4 PRODUCT PORTFOLIO
  5. 11.6.5 BUSINESS PERFORMANCE
  6. 11.6.6 BUSINESS SEGMENTS
  7. 11.6.7 GEOGRAPHIC SEGMENTS
  8. 11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.6.9 PRIMARY MARKET COMPETITORS
13. 11.7 SIEMENS HEALTHINEERS AG
14. 1. 11.7.1 COMPANY OVERVIEW
  2. 11.7.2 COMPANY SNAPSHOT
  3. 11.7.3 OPERATING BUSINESS SEGMENTS
  4. 11.7.4 PRODUCT PORTFOLIO
  5. 11.7.5 BUSINESS PERFORMANCE
  6. 11.7.6 BUSINESS SEGMENTS
  7. 11.7.7 GEOGRAPHIC SEGMENTS
  8. 11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.7.9 PRIMARY MARKET COMPETITORS
15. 11.8 BIOMÉRIEUX SA
16. 1. 11.8.1 COMPANY OVERVIEW
  2. 11.8.2 COMPANY SNAPSHOT
  3. 11.8.3 OPERATING BUSINESS SEGMENTS
  4. 11.8.4 PRODUCT PORTFOLIO
  5. 11.8.5 BUSINESS PERFORMANCE
  6. 11.8.6 BUSINESS SEGMENTS
  7. 11.8.7 GEOGRAPHIC SEGMENTS
  8. 11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.8.9 PRIMARY MARKET COMPETITORS
17. 11.9 SYSMEX CORPORATION
18. 1. 11.9.1 COMPANY OVERVIEW
  2. 11.9.2 COMPANY SNAPSHOT
  3. 11.9.3 OPERATING BUSINESS SEGMENTS
  4. 11.9.4 PRODUCT PORTFOLIO
  5. 11.9.5 BUSINESS PERFORMANCE
  6. 11.9.6 BUSINESS SEGMENTS
  7. 11.9.7 GEOGRAPHIC SEGMENTS
  8. 11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.9.9 PRIMARY MARKET COMPETITORS
19. 11.10 QIAGEN N.V.
20. 1. 11.10.1 COMPANY OVERVIEW
  2. 11.10.2 COMPANY SNAPSHOT
  3. 11.10.3 OPERATING BUSINESS SEGMENTS
  4. 11.10.4 PRODUCT PORTFOLIO
  5. 11.10.5 BUSINESS PERFORMANCE
  6. 11.10.6 BUSINESS SEGMENTS
  7. 11.10.7 GEOGRAPHIC SEGMENTS
  8. 11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.10.9 PRIMARY MARKET COMPETITORS
21. 11.11 BIO-RAD LABORATORIES, INC.
22. 1. 11.11.1 COMPANY OVERVIEW
  2. 11.11.2 COMPANY SNAPSHOT
  3. 11.11.3 OPERATING BUSINESS SEGMENTS
  4. 11.11.4 PRODUCT PORTFOLIO
  5. 11.11.5 BUSINESS PERFORMANCE
  6. 11.11.6 BUSINESS SEGMENTS
  7. 11.11.7 GEOGRAPHIC SEGMENTS
  8. 11.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.11.9 PRIMARY MARKET COMPETITORS
23. 11.12 ILLUMINA AFRICA
24. 1. 11.12.1 COMPANY OVERVIEW
  2. 11.12.2 COMPANY SNAPSHOT
  3. 11.12.3 OPERATING BUSINESS SEGMENTS
  4. 11.12.4 PRODUCT PORTFOLIO
  5. 11.12.5 BUSINESS PERFORMANCE
  6. 11.12.6 BUSINESS SEGMENTS
  7. 11.12.7 GEOGRAPHIC SEGMENTS
  8. 11.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.12.9 PRIMARY MARKET COMPETITORS
25. 11.13 NIHON KOHDEN CORPORATION
26. 1. 11.13.1 COMPANY OVERVIEW
  2. 11.13.2 COMPANY SNAPSHOT
  3. 11.13.3 OPERATING BUSINESS SEGMENTS
  4. 11.13.4 PRODUCT PORTFOLIO
  5. 11.13.5 BUSINESS PERFORMANCE
  6. 11.13.6 BUSINESS SEGMENTS
  7. 11.13.7 GEOGRAPHIC SEGMENTS
  8. 11.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.13.9 PRIMARY MARKET COMPETITORS
27. 11.14 DIASORIN
28. 1. 11.14.1 COMPANY OVERVIEW
  2. 11.14.2 COMPANY SNAPSHOT
  3. 11.14.3 OPERATING BUSINESS SEGMENTS
  4. 11.14.4 PRODUCT PORTFOLIO
  5. 11.14.5 BUSINESS PERFORMANCE
  6. 11.14.6 BUSINESS SEGMENTS
  7. 11.14.7 GEOGRAPHIC SEGMENTS
  8. 11.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.14.9 PRIMARY MARKET COMPETITORS
29. 11.15 AGILENT TECHNOLOGIES, INC
30. 1. 11.15.1 COMPANY OVERVIEW
  2. 11.15.2 COMPANY SNAPSHOT
  3. 11.15.3 OPERATING BUSINESS SEGMENTS
  4. 11.15.4 PRODUCT PORTFOLIO
  5. 11.15.5 BUSINESS PERFORMANCE
  6. 11.15.6 BUSINESS SEGMENTS
  7. 11.15.7 GEOGRAPHIC SEGMENTS
  8. 11.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 11.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 2. REAGENTS , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 3. INSTRUMENTS , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 4. SOFTWARE AND SERVICES , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 5. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 7. RAPID TESTS, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 8. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 9. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 10. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 11. WESTERN BLOT, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 12. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 14. PCR, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 15. INAAT, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 16. HYBRIDIZATION, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 17. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 18. MICROARRAY, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 19. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 20. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 21. TISSUE DISGNOSTICS , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 22. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 23. LIVER PANEL, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 24. RENAL PROFILE, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 25. LIPID PROFILE, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 26. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 27. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 28. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY 2024-2030, (BILLION USD)
TABLE 29. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 31. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 32. INFECTIOUS DISEASES , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 33. CANCER , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 34. CARDIAC DISEASES , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 38. OTHER INDICATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 39. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 44. OTHER END-USERS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 45. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 46. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 47. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 48. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 49. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 50. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 51. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 52. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 53. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 54. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 55. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 56. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 57. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 58. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 59. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 60. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 61. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 62. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 63. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 64. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 65. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 66. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 67. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 68. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 69. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 70. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 71. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 72. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 73. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 74. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 75. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 76. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 77. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 78. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 79. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 80. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 81. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 82. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 83. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 84. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 85. ROCHE HOLDING AG: KEY STRATERGY
TABLE 86. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: COMPANY SNAPSHOT
TABLE 87. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: OPERATING BUSINESS SEGMENTS
TABLE 88. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: PRODUCT PORTFOLIO
TABLE 89. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 90. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 91. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: KEY STRATERGY
TABLE 92. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 93. THERMO FISHER SCIENTIFIC INC: OPERATING BUSINESS SEGMENTS
TABLE 94. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 95. THERMO FISHER SCIENTIFIC INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 96. THERMO FISHER SCIENTIFIC INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 97. THERMO FISHER SCIENTIFIC INC: KEY STRATERGY
TABLE 98. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 99. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 100. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 101. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 102. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 103. DANAHER CORPORATION: KEY STRATERGY
TABLE 104. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 105. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 106. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 107. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 108. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 109. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 110. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 111. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 112. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 113. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 114. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 115. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 116. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 117. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 118. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 119. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 120. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 121. BIOMéRIEUX SA: KEY STRATERGY
TABLE 122. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 123. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 124. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 125. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 126. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 127. SYSMEX CORPORATION: KEY STRATERGY
TABLE 128. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 129. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 130. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 131. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 132. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 133. QIAGEN N.V.: KEY STRATERGY
TABLE 134. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 135. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 136. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 137. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 138. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 139. BIO-RAD LABORATORIES, INC.: KEY STRATERGY
TABLE 140. ILLUMINA AFRICA: COMPANY SNAPSHOT
TABLE 141. ILLUMINA AFRICA: OPERATING BUSINESS SEGMENTS
TABLE 142. ILLUMINA AFRICA: PRODUCT PORTFOLIO
TABLE 143. ILLUMINA AFRICA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 144. ILLUMINA AFRICA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 145. ILLUMINA AFRICA: KEY STRATERGY
TABLE 146. NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT
TABLE 147. NIHON KOHDEN CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 148. NIHON KOHDEN CORPORATION: PRODUCT PORTFOLIO
TABLE 149. NIHON KOHDEN CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 150. NIHON KOHDEN CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 151. NIHON KOHDEN CORPORATION: KEY STRATERGY
TABLE 152. DIASORIN: COMPANY SNAPSHOT
TABLE 153. DIASORIN: OPERATING BUSINESS SEGMENTS
TABLE 154. DIASORIN: PRODUCT PORTFOLIO
TABLE 155. DIASORIN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 156. DIASORIN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 157. DIASORIN: KEY STRATERGY
TABLE 158. AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT
TABLE 159. AGILENT TECHNOLOGIES, INC: OPERATING BUSINESS SEGMENTS
TABLE 160. AGILENT TECHNOLOGIES, INC: PRODUCT PORTFOLIO
TABLE 161. AGILENT TECHNOLOGIES, INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 162. AGILENT TECHNOLOGIES, INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 163. AGILENT TECHNOLOGIES, INC: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
FIGURE 7. REAGENTS , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 8. INSTRUMENTS , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 9. SOFTWARE AND SERVICES , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 10. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
FIGURE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 12. RAPID TESTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 15. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 16. WESTERN BLOT, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 17. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 19. PCR, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 20. INAAT, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 21. HYBRIDIZATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 22. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 23. MICROARRAY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 24. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 26. TISSUE DISGNOSTICS , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 27. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 28. LIVER PANEL, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 29. RENAL PROFILE, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 30. LIPID PROFILE, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 31. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 32. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 33. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 34. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 36. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
FIGURE 37. INFECTIOUS DISEASES , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 38. CANCER , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 39. CARDIAC DISEASES , MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 43. OTHER INDICATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 44. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 49. OTHER END-USERS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 50. AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY REGION 2024-2030, (BILLION USD)
FIGURE 51. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 52. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 53. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 54. SOUTH AFRICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 55. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 56. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 57. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 58. NIGERIA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 59. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 60. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 61. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 62. GHANA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 63. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 64. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 65. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 66. KENYA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 67. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 68. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 69. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 70. MOROCCO IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 71. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 72. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 73. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 74. EGYPT IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 75. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT TYPE 2024-2030, (BILLION USD)
FIGURE 76. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2024-2030, (BILLION USD)
FIGURE 77. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2024-2030, (BILLION USD)
FIGURE 78. OTHER AFRICAN COUNTRIES IN-VITRO DIAGNOSTICS MARKET VALUE, BY END-USER 2024-2030, (BILLION USD)
FIGURE 79. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 80. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 81. ROCHE HOLDING AG: NET SALES, (2022-2024)
FIGURE 82. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 83. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: NET SALES, (2022-2024)
FIGURE 84. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: PRIMARY MARKET COMPETITORS
FIGURE 85. THERMO FISHER SCIENTIFIC INC: NET SALES, (2022-2024)
FIGURE 86. THERMO FISHER SCIENTIFIC INC: PRIMARY MARKET COMPETITORS
FIGURE 87. DANAHER CORPORATION: NET SALES, (2022-2024)
FIGURE 88. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 89. BECTON, DICKINSON AND COMPANY: NET SALES, (2022-2024)
FIGURE 90. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 91. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 92. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 93. BIOMéRIEUX SA: NET SALES, (2022-2024)
FIGURE 94. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 95. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 96. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 97. QIAGEN N.V.: NET SALES, (2022-2024)
FIGURE 98. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 99. BIO-RAD LABORATORIES, INC.: NET SALES, (2022-2024)
FIGURE 100. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS
FIGURE 101. ILLUMINA AFRICA: NET SALES, (2022-2024)
FIGURE 102. ILLUMINA AFRICA: PRIMARY MARKET COMPETITORS
FIGURE 103. NIHON KOHDEN CORPORATION: NET SALES, (2022-2024)
FIGURE 104. NIHON KOHDEN CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 105. DIASORIN: NET SALES, (2022-2024)
FIGURE 106. DIASORIN: PRIMARY MARKET COMPETITORS
FIGURE 107. AGILENT TECHNOLOGIES, INC: NET SALES, (2022-2024)
FIGURE 108. AGILENT TECHNOLOGIES, INC: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Africa in-vitro diagnostics market revenue is estimated to reach up to USD 1.45 billion by 2030.

The key players operating in the Africa in-vitro diagnostics market include Abbott Laboratories, Roche Holding AG , Mindray Bio-Medical Electronics Co.,Ltd., Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina Africa, Nihon Kohden Corporation , DiaSorin, , Agilent Technologies, Inc, and others

The Africa in-vitro diagnostics market size was estimated at USD 0.93 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the Africa IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the Africa in-vitro diagnostics market, in the coming future.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Purchase Options Flash
sale

Multi User

$3,917 $5595

Single User

$3,217 $4595

Enterprise

$5,317 $7595

Datapack

$1,817 $2595

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

Request Sample